INCA-32459

N/A

Report date: 2025/05/14 18:14:08

Base Information

Drug NameINCA-32459

Drug Alias NameINCA-32459

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionLymphocyte activation gene 3 protein inhibitorsAnti-PD-1

TargetsLymphocyte activation gene 3 proteinProgrammed cell death protein 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumUnited StatesItaly +[4]

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesIncyte Corp Merus Nv

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesIncyte Corp Merus Nv

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A